On the occasion of obtaining NPS-2, a blood sample (BS-1) was collected from each person enrolled in the study. A second blood sample (BS-2) was subsequently collected two weeks after BS-1.

Serum was prepared from the blood samples for antibody detection. Detection of anti-nucleocapsid (anti-N) and anti-spike (anti-S) IgG antibodies was performed using the commercial assays Elecsys®® Anti-SARS-CoV-2 and Elecsys®® Anti-SARS-CoV-2 S, respectively, in a cobas e 602 module (Roche, Basel, Switzerland).

With regard to anti-N antibodies, values for the ratio S/Co < 1 were considered to be negative and values ≥ 1 were considered to be positive. With regard to anti-S antibodies, values < 0.8 μL−1 were considered to be negative and values ≥ 0.8 μL−1 were considered to be positive.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.